NewAmsterdam Pharma Company N.V. (NAMSW) Operating income 2021–2025
NewAmsterdam Pharma Company N.V. (NAMSW) annual operating income history from SEC filings — each fiscal year as reported.
-$225.7MFY2025 · since FY2021: -$35.0M → -$225.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$225.7M | -28.0% |
| FY2024 | -$176.3M | +3.6% |
| FY2023 | -$183.0M | -5043.9% |
| FY2022 | -$3.6M | +89.8% |
| FY2021 | -$35.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMSW financial trends
NAMSW RevenueNAMSW Net incomeNAMSW Net marginNAMSW Gross profitNAMSW Gross marginNAMSW Operating marginNAMSW Operating cash flowNAMSW Free cash flowNAMSW Capital expendituresNAMSW Return on equityNAMSW Stock buybacksNAMSW Dividends paidNAMSW Total assetsNAMSW Total liabilitiesNAMSW Shareholders’ equityNAMSW overview →